AstraZeneca Pulls Covid-19 Vaccine Over Thrombosis Concerns

Cambridge, 8th May 2024: AstraZeneca announced on Tuesday its global recall of the Covid-19 vaccine, citing the rare side effect Thrombosis with Thrombocytopenia Syndrome (TTS). This decision follows the acknowledgement of potential side effects, including blood clots and reduced blood platelet counts, previously noted in legal documents.

The withdrawal is attributed to an excess supply of updated vaccines amid the pandemic. The company emphasized the decline in demand for its vaccine, Vaxzevria, which is no longer in production or distribution within Europe. AstraZeneca, in collaboration with the University of Oxford, faces legal challenges alleging severe harm and fatalities linked to the vaccine.

The withdrawal application, submitted on March 5 and effective on May 7, comes amidst ongoing legal proceedings. One plaintiff, Jamie Scott, reported suffering a blood clot and brain injury post-vaccination. While the company acknowledges the vaccine’s potential rare side effect of TTS, it asserts uncertainty regarding the causal mechanism.

AstraZeneca expressed condolences for affected individuals and families, affirming commitment to patient safety and the vaccine’s overall safety profile, as supported by clinical and real-world data. High Court filings indicate 51 cases seeking compensation totalling an estimated £100 million.